DYN Dyne Therapeutics, Inc.

NASDAQ
$16.70

Dyne Therapeutics, Inc. (DYN) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.93 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.1% since its last earnings release on November 5, 2026.

Dyne Therapeutics, Inc. Missed Expectations
Thursday, November 5, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · After Close
Earnings Whisper
-
vs ($0.93)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $17.70

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Dyne Therapeutics, Inc.

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.